Episodic Ataxia Type 1
文献摘要
Clinical characteristics Episodic ataxia type 1 (EA1) is a potassium channelopathy characterized by constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance. During attacks individuals may experience a number of variable symptoms including dysarthria, stiffening of the body, blurred vision, diplopia, nausea, headache, vertigo, diaphoresis, clumsiness, and difficulty in breathing, among others. EA1 may be associated with epilepsy. Other possible associations include delayed motor development, cognitive disability, choreoathetosis, and carpal spasm. Usually, onset is in childhood or early adolescence. Diagnosis/testing The diagnosis of EA1 is established in a proband with characteristic clinical findings, electrophysiologic evidence of axonal hyperexcitability, and a heterozygous pathogenic variant in KCNA1 identified by molecular genetic testing. Management Treatment of manifestations: Acetazolamide, a carbonic-anhydrase inhibitor, may reduce the frequency and severity of attacks in some but not all affected individuals. Anti-seizure medication may significantly reduce the frequency of attacks in some individuals. Supportive therapies, such as physical therapy, may reduce the risk of later-onset orthopedic complications. Routine treatment of seizure disorders, scoliosis, and developmental disabilities. Surveillance: Annual neurologic examination; EEG as needed; at each visit assess developmental and educational progress, mobility, self-help skills, and family needs. Agents/circumstances to avoid: Triggers of attacks, including physical exertion, sudden movements, loud noises, emotional stress, and changes in environmental temperature. Marked generalized myokymia has been reported during induction of anesthesia. Evaluation of relatives at risk: Offer molecular genetic testing for the familial KCNA1 pathogenic variant to apparently asymptomatic older and younger at-risk relatives of an affected individual in order to identify affected individuals as early as possible and facilitate avoidance of known disease triggers. Pregnancy management: Affected women should be made aware that pregnancy may trigger attacks; possible loss of balance and falls could endanger the fetus. Several stressors that trigger attacks may cause breathing difficulties; thus, delivery by cesarean section should be considered. Genetic counseling EA1 is inherited in an autosomal dominant manner. Most individuals diagnosed with EA1 have an affected parent; however, de novo pathogenic variants have been reported. Each child of an individual with EA1 has a 50% chance of inheriting the KCNA1 pathogenic variant. Significant clinical variability may be observed among affected family members, including differences in the severity and frequency of EA1 attacks. Once the KCNA1 pathogenic variant has been identified in an affected family member, prenatal and preimplantation genetic testing are possible.